An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Trial Profile

An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 31 May 2017 Status changed from not yet recruiting to recruiting.
    • 28 Apr 2017 Planned End Date changed from 1 Dec 2020 to 25 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top